PSMA

Advancements in gallium-based radiopharmaceuticals are transforming the landscape of oncologic diagnostics, with several agents already in routine clinical practice and more in development. Explore the techniques employed to produce the gallium-68 on both small and large scales to satisfy clinical and research needs.

Professor Nagarajah guides us through the latest developments in PSMA-targeting radiopharmaceuticals and shares his views on the role of dosimetry in radionuclide therapy.